Agreed @Deebo. My take from the Spark report is that right now PAA is valued at ~$1,00 per share (not 16 cents) AND that values MPL only for MND and canine cancer taking into account all the remaining risks through to commercialization.
The $1.00 excludes all there treatment possibilities, so why are people selling....its a ridiculously low price to sell out at......tight fists required.
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-389
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.42M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.3¢ | 19.0¢ | $25.41K | 133.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5372 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 262575 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |